AUPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AUPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-29), Aurinia Pharmaceuticals's share price is $5.01. Aurinia Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.24. Hence, Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:
Aurinia Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.10. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.24.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 28.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 12.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 2.50% per year.
During the past 13 years, Aurinia Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 55.70% per year. The lowest was -49.50% per year. And the median was 6.40% per year.
The historical data trend for Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Aurinia Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow falls into.
Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 5.01 | / | -0.24 | |
= | N/A |
Aurinia Pharmaceuticals's Share Price of today is $5.01.
Aurinia Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Aurinia Pharmaceuticals (NAS:AUPH) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert T Foster | director | C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837 |
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Jeffrey Allen Bailey | director | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612 |
R. Hector Mackay-dunn | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
Jayne David R.w. | director | #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8 |
Jill Leversage | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Daniel Billen | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Joseph P Hagan | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
Brinda Balakrishnan | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
Peter Greenleaf | director, officer: Chief Executive Officer | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Joseph M Miller | officer: Chief Financial Officer | C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Stephen P. Robertson | officer: EVP, General Counsel | #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8 |
Milne George M Jr | director | |
Matthew Maxwell Donley | officer: Ex VP, Intern'l Operations | 4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814 |
Scott Michael Habig | officer: Chief Commercial Officer | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
From GuruFocus
By Business Wire Business Wire • 04-28-2023
By Business Wire Business Wire • 04-24-2023
By Business Wire • 11-02-2023
By Business Wire • 11-07-2023
By Business Wire • 08-03-2023
By Business Wire Business Wire • 05-26-2023
By Business Wire Business Wire • 05-03-2023
By Business Wire • 08-21-2023
By Business Wire • 07-19-2023
By Business Wire Business Wire • 02-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.